

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT IN RELATION TO THE APPROVAL OBTAINED FROM THE ISSUANCE EXAMINATION COMMITTEE OF THE CSRC FOR THE PROPOSED NON-PUBLIC ISSUANCE

References are made to the announcements of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) dated 25 November 2020 and 6 April 2021, the overseas regulatory announcements of the Company dated 25 November 2020, 15 January 2021, 22 February 2021, 6 April 2021, 1 June 2021 and 5 July 2021, and the circular of the Company dated 8 December 2020 (the “**Circular**”), in relation to the Proposed Non-public Issuance. Unless otherwise specified, capitalised terms used in this announcement shall have the same meaning as defined in the Circular.

On 12 July 2021, the Issuance Examination Committee of the CSRC reviewed the Proposed Non-public Issuance. According to the review results, the application for the Proposed Non-public Issuance was approved.

As at the date of this announcement, the Company has not received the CSRC’s written approval documents, and the Company will make further announcement upon the receipt of the official written approval from the CSRC.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC

12 July 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* for identification purposes only